Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

$18.4 Million In User Fees Left In CDRH’s Coffers, How Long Will It Last?

This article was originally published in The Gray Sheet

Executive Summary

The device center says it had $18.4 million in user fees remaining as of Oct. 1 to continue its work focused solely on user-fee funded activities, but the agency is unsure how long the funds will last if the government shutdown continues.

Advertisement

Related Content

News Briefs: Teleflex Acquires Vidacare; Integra Buys Covidien’s DuraSeal Line
Addressing The Device Backlog: Government Shutdown Ends, Now FDA Has To Catch Up
Addressing The Backlog: Government Shutdown Ends, Now FDA Has To Catch Up
CardioMEMS Has Better Luck With FDA Advisory Panel Second Time Around
Shutdown Realities At FDA: No New Submission Reviews, And More
Regulatory Briefs: U.K. Trials Database; Hospitals Seek UDI Rule; FDA Workshops
News Briefs: FDA Program Alignment Group; CardioMEMS Panel; HCV Coverage Analysis

Topics

Advertisement
UsernamePublicRestriction

Register

MT032490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel